Galina A. Klyasova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Galina A. Klyasova has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Elena Parovichnikova
National Medical Research Center of Hematology
12 shared publications - Larisa A. Kuzmina
National Medical Research Center for Hematology
10 shared publications - Anastasia Fedorova
National Medical Research Center for Hematology, Ministry of Health of Russia
9 shared publications - Valerii G. Savchenko
National Medical Research Center for Hematology
9 shared publications - Elena O. Gribanova
National Medical Research Center for Hematology
5 shared publications - Mikhail Yu. Drokov
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
5 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (1) , 59
Early Antifungal Treatment in Immunocompromised Patients, Including Hematological and Critically Ill Patients
(1) Background: Invasive fungal diseases (IFDs) represent significant challenges in clinical practice, particularly among immunocompromised individuals, leading to substantial morbidity and mortality. The present document aims to provide evidence-based consensus for the timely initiation of antifungal treatment, focusing on early empiric approaches among immunocompromised patients. (2) Methods: A multidisciplinary expert panel of nine healthcare professionals (HCPs) reviewed the literature, including guidelines and consensus reports (2013–2023; PubMed, Scopus). The panel defined appropriate empiric antifungal approaches for invasive candidiasis, aspergillosis, and mucormycosis among hematological and critically ill patients. Consensus was defined as ≥75% agreement. (3) Results: A total of 47 statements were included. The experts recommend that early targeted antifungal therapy is critical for high-risk patients with suspected IFDs. Empiric therapy may be initiated before definitive diagnosis, considering the local fungal prevalence and the patient’s risk category. Close monitoring is essential, and switching between antifungal classes may be necessary for patients who experience deterioration or side effects. The transition from intravenous to oral therapy depends on the specific infection, the availability of therapeutic drug monitoring, and the patient’s progress. (4) Conclusions: Implementing this targeted, early approach may improve the outcomes of vulnerable patients with IFDs.
- 13 January 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (1) , 59
Open AccessEarly Antifungal Treatment in Immunocompromised Patients, Including Hematological and Critically Ill Patients
(1) Background: Invasive fungal diseases (IFDs) represent significant challenges in clinical practice, particularly among immunocompromised individuals, leading to substantial morbidity and mortality. The present document aims to provide evidence-based consensus for the timely initiation of antifungal treatment, focusing on early empiric approaches among immunocompromised patients. (2) Methods: A multidisciplinary expert panel of nine healthcare professionals (HCPs) reviewed the literature, including guidelines and consensus reports (2013–2023; PubMed, Scopus). The panel defined appropriate empiric antifungal approaches for invasive candidiasis, aspergillosis, and mucormycosis among hematological and critically ill patients. Consensus was defined as ≥75% agreement. (3) Results: A total of 47 statements were included. The experts recommend that early targeted antifungal therapy is critical for high-risk patients with suspected IFDs. Empiric therapy may be initiated before definitive diagnosis, considering the local fungal prevalence and the patient’s risk category. Close monitoring is essential, and switching between antifungal classes may be necessary for patients who experience deterioration or side effects. The transition from intravenous to oral therapy depends on the specific infection, the availability of therapeutic drug monitoring, and the patient’s progress. (4) Conclusions: Implementing this targeted, early approach may improve the outcomes of vulnerable patients with IFDs.
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 108-117
Coagulase-negative staphylococci from blood cultures – infection or contamination?
Background. Coagulase-negative staphylococci (CoNS) are one of the leading causative agents of bloodstream infections. At the same time, CoNS are part of the normal skin flora and can contaminate blood culture samples taken from patients. Aim. To characterize episodes of bloodstream infection and blood culture contamination caused by CoNS in patients with hematological diseases. Materials and methods. The frequency of CoNS detection from blood cultures was analyzed in patients hospitalized at the National Medical Research Center for Hematology in Moscow from January 1, 2022 to December 31, 2022. Blood for microbiology testing was taken from a patient with fever ≥38 °C into two bottles (aerobic / anaerobic) simultaneously from a vein and a central venous catheter or only from a vein. Blood bottles were incubated in an automatic blood culture analyzer (BD BACTEC FX, Becton Dickinson). Isolation of CoNS from only one of two blood culture samples was considered contamination. Results. CoNS were isolated from blood cultures in 90 patients (48 men and 42 women, median age 45.5 years). A total of 101 episodes of CoNS isolation were recorded, of which infection was diagnosed in 32 (31.7 %) cases, including 20 (62.5 %) bloodstream infections and 12 (37.5 %) catheter-associated bloodstream infections, while contamination was identified in 69 (68.3 %) cases. CoNS blood culture contamination was significantly less frequent than infection in patients with leukopenia (50.7 % vs 78.1 %; p = 0.03). The median duration of continuous hospitalization was significantly longer in patients with infection than in those with contamination (40.5 vs 16 days; p = 0.02). A total of 102 CoNS strains were isolated; rarer species such as Staphylococcus capitis, S. caprae, and S. warneri were isolated only in contamination cases. The median time to the positive blood culture signal was significantly shorter in infections than in CoNS contamination (14 hours 25 minutes vs 22 hours 10 minutes; p 0.0001). Most patients (75 %) received vancomycin. No cases of attributable mortality were identified. Conclusion. A high frequency of CoNS blood culture contamination (68.3 %) was determined, highlighting the critical importance of proper blood collection technique for microbiological examination. In contrast to infection, longer incubation time in the analyzer, isolation outside leukopenia, and shorter hospitalization duration were associated with CoNS contamination.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 108-117
Open AccessCoagulase-negative staphylococci from blood cultures – infection or contamination?
Background. Coagulase-negative staphylococci (CoNS) are one of the leading causative agents of bloodstream infections. At the same time, CoNS are part of the normal skin flora and can contaminate blood culture samples taken from patients. Aim. To characterize episodes of bloodstream infection and blood culture contamination caused by CoNS in patients with hematological diseases. Materials and methods. The frequency of CoNS detection from blood cultures was analyzed in patients hospitalized at the National Medical Research Center for Hematology in Moscow from January 1, 2022 to December 31, 2022. Blood for microbiology testing was taken from a patient with fever ≥38 °C into two bottles (aerobic / anaerobic) simultaneously from a vein and a central venous catheter or only from a vein. Blood bottles were incubated in an automatic blood culture analyzer (BD BACTEC FX, Becton Dickinson). Isolation of CoNS from only one of two blood culture samples was considered contamination. Results. CoNS were isolated from blood cultures in 90 patients (48 men and 42 women, median age 45.5 years). A total of 101 episodes of CoNS isolation were recorded, of which infection was diagnosed in 32 (31.7 %) cases, including 20 (62.5 %) bloodstream infections and 12 (37.5 %) catheter-associated bloodstream infections, while contamination was identified in 69 (68.3 %) cases. CoNS blood culture contamination was significantly less frequent than infection in patients with leukopenia (50.7 % vs 78.1 %; p = 0.03). The median duration of continuous hospitalization was significantly longer in patients with infection than in those with contamination (40.5 vs 16 days; p = 0.02). A total of 102 CoNS strains were isolated; rarer species such as Staphylococcus capitis, S. caprae, and S. warneri were isolated only in contamination cases. The median time to the positive blood culture signal was significantly shorter in infections than in CoNS contamination (14 hours 25 minutes vs 22 hours 10 minutes; p 0.0001). Most patients (75 %) received vancomycin. No cases of attributable mortality were identified. Conclusion. A high frequency of CoNS blood culture contamination (68.3 %) was determined, highlighting the critical importance of proper blood collection technique for microbiological examination. In contrast to infection, longer incubation time in the analyzer, isolation outside leukopenia, and shorter hospitalization duration were associated with CoNS contamination.
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 51-62
Efficacy of second autologous stem cell transplantation in patients with multiple myeloma
Background. Therapeutic options for patients with relapsed multiple myeloma (MM) after primary autologous hematopoietic stem cell transplantation (auto-HSCT) may include not only modern targeted therapies but also second auto-HSCT. Aim. To evaluate the efficacy of second auto-HSCT in the treatment of the first MM relapse, to identify prognostic factors influencing progression-free survival (PFS) and overall survival (OS), and to compare the early post-transplantation period following primary and second auto-HSCT. Materials and methods. This retrospective study included 23 patients (13 men and 10 women, median age 52 years) with MM who underwent primary auto-HSCT as consolidation after induction therapy and second auto-HSCT during the treatment of their first disease relapse. The effect of second auto-HSCT was assessed based on PFS and OS. In addition, the analysis of results also considered the PFS from primary auto-HSCT to the first relapse / disease progression. Results. The median PFS after second auto-HSCT was 26 months. Survival outcomes were significantly better in patients with a PFS of more than 18 months after primary auto-HSCT compared to those with a PFS of less than 18 months (median 32 months vs 9 months). Overall survival outcomes after second auto-HSCT were highly encouraging: the median OS was 75 months, with 3-year survival reaching 82 % and 6-year survival – 70 %. Second auto-HSCT was not associated with a higher risk of infectious complications in the early post-transplant period or a prolonged recovery of blood count parameters compared to primary auto-HSCT. Conclusion. Based on our results and literature data, second auto-HSCT can be safely performed in most MM patients who have relapsed after primary auto-HSCT.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 51-62
Open AccessEfficacy of second autologous stem cell transplantation in patients with multiple myeloma
Background. Therapeutic options for patients with relapsed multiple myeloma (MM) after primary autologous hematopoietic stem cell transplantation (auto-HSCT) may include not only modern targeted therapies but also second auto-HSCT. Aim. To evaluate the efficacy of second auto-HSCT in the treatment of the first MM relapse, to identify prognostic factors influencing progression-free survival (PFS) and overall survival (OS), and to compare the early post-transplantation period following primary and second auto-HSCT. Materials and methods. This retrospective study included 23 patients (13 men and 10 women, median age 52 years) with MM who underwent primary auto-HSCT as consolidation after induction therapy and second auto-HSCT during the treatment of their first disease relapse. The effect of second auto-HSCT was assessed based on PFS and OS. In addition, the analysis of results also considered the PFS from primary auto-HSCT to the first relapse / disease progression. Results. The median PFS after second auto-HSCT was 26 months. Survival outcomes were significantly better in patients with a PFS of more than 18 months after primary auto-HSCT compared to those with a PFS of less than 18 months (median 32 months vs 9 months). Overall survival outcomes after second auto-HSCT were highly encouraging: the median OS was 75 months, with 3-year survival reaching 82 % and 6-year survival – 70 %. Second auto-HSCT was not associated with a higher risk of infectious complications in the early post-transplant period or a prolonged recovery of blood count parameters compared to primary auto-HSCT. Conclusion. Based on our results and literature data, second auto-HSCT can be safely performed in most MM patients who have relapsed after primary auto-HSCT.
- Open Access
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 84-96
Invasive fungal diseases in recipients of allogeneic hematopoietic stem cells: current state of the problem
Allogeneic hematopoietic stem cell transplantation is a standard treatment option for a variety of hematological disorders. In recent years, there has been observed an increase in transplantation activity worldwide as well as in use of alternative donors. Despite introduction of antifungal prophylaxis, recipients of allogeneic hematopoietic stem cells still have a high risk of invasive fungal disease.This review represents risk factors, frequency and structure of invasive fungal disease in this category of patients.
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 84-96
Open AccessInvasive fungal diseases in recipients of allogeneic hematopoietic stem cells: current state of the problem
Allogeneic hematopoietic stem cell transplantation is a standard treatment option for a variety of hematological disorders. In recent years, there has been observed an increase in transplantation activity worldwide as well as in use of alternative donors. Despite introduction of antifungal prophylaxis, recipients of allogeneic hematopoietic stem cells still have a high risk of invasive fungal disease.This review represents risk factors, frequency and structure of invasive fungal disease in this category of patients.
- Open Access
- 10 July 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (2) , 189-199
Pathogens of periprosthetic infection in patients with hemophilia
Introduction. Endoprosthetics remains the only method of treating end-stage arthropathy in patients with hemophilia. Along with the increase in the number of endoprosthetics, the number of periprosthetic infections is also on the rise.Objective. to determine the most common pathogens and their sensitivity to antimicrobial drugs, as well as risk factors for the development of periprosthetic infections in patients with hemophilia after endoprosthetics of large joints.Materials and methods. A retrospective study analyzed cases of PJI of large joints in patients with hemophilia between 2015 and 2022, along with the causative agents of this complication.Results. A total of 80 cases of PJI were identified. In patients with hemophilia A, PJI occurred in 76.0% of cases (61 patients), in patients with hemophilia B in 24.0% of cases (19 patients). Primary infection was detected in 47.5% of cases (38 PJI). Relapse of infection was detected in 42 episodes (52.5%). A washing system with dioxidine or polyhexadine was used in 9 cases (11.2%) of primary infection, in all other cases a two-stage revision tactic was used. 20 different pathogens were identified: 58 (65.0%) episodes of gram-positive flora, 13 (14.0%) cases of gram-negative flora, 3 (3.0%) episodes of fungal infection. It was not possible to identify the pathogen in 16 (18.0%) cases. The most common pathogens were S. aureus (21.1%) and S. epidermidis (21.1%), E. faecalis (7.3%). Among Staphylococcus aureus isolates, 18.8% were methicillin-resistant strains. Among gram-negative bacteria, P. aeruginosa was detected in 6 cases (7.3%), all of which exhibited multiple antibiotic resistance. The number of cases of PJI that arose in the first month or first year did not differ significantly from episodes when infectious complications arose in the period of a year or more. PJI after revision endoprosthetics most often debuted within 12 months after surgery.Conclusion. The highest risk of PJI in patients with hemophilia occurs within the first year after revision endoprosthetics. PJI develops more frequently in patients with hemophilia than the general population, which is attributed to a greater number of risk factors in patients with hemophilia compared to the general patient population.
- 10 July 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (2) , 189-199
Open AccessPathogens of periprosthetic infection in patients with hemophilia
Introduction. Endoprosthetics remains the only method of treating end-stage arthropathy in patients with hemophilia. Along with the increase in the number of endoprosthetics, the number of periprosthetic infections is also on the rise.Objective. to determine the most common pathogens and their sensitivity to antimicrobial drugs, as well as risk factors for the development of periprosthetic infections in patients with hemophilia after endoprosthetics of large joints.Materials and methods. A retrospective study analyzed cases of PJI of large joints in patients with hemophilia between 2015 and 2022, along with the causative agents of this complication.Results. A total of 80 cases of PJI were identified. In patients with hemophilia A, PJI occurred in 76.0% of cases (61 patients), in patients with hemophilia B in 24.0% of cases (19 patients). Primary infection was detected in 47.5% of cases (38 PJI). Relapse of infection was detected in 42 episodes (52.5%). A washing system with dioxidine or polyhexadine was used in 9 cases (11.2%) of primary infection, in all other cases a two-stage revision tactic was used. 20 different pathogens were identified: 58 (65.0%) episodes of gram-positive flora, 13 (14.0%) cases of gram-negative flora, 3 (3.0%) episodes of fungal infection. It was not possible to identify the pathogen in 16 (18.0%) cases. The most common pathogens were S. aureus (21.1%) and S. epidermidis (21.1%), E. faecalis (7.3%). Among Staphylococcus aureus isolates, 18.8% were methicillin-resistant strains. Among gram-negative bacteria, P. aeruginosa was detected in 6 cases (7.3%), all of which exhibited multiple antibiotic resistance. The number of cases of PJI that arose in the first month or first year did not differ significantly from episodes when infectious complications arose in the period of a year or more. PJI after revision endoprosthetics most often debuted within 12 months after surgery.Conclusion. The highest risk of PJI in patients with hemophilia occurs within the first year after revision endoprosthetics. PJI develops more frequently in patients with hemophilia than the general population, which is attributed to a greater number of risk factors in patients with hemophilia compared to the general patient population.
- Open Access
- 27 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 392-409
Multicenter randomized controlled (comparative) open prospective study to evaluate the efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cell transplantation programs in untreated patients with de novo diffuse B-cell large cell lymphoma with signs of poor prognosis (final results)
Introduction. The R-NHL-BFM-90 protocol has been successfully used for the treatment of Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) in children and adolescents, as well as adult T-cell lymphomas. The protocol was modified for the treatment of adult patients with de novo nodal DLBCL.Aim: to evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DA-EPOCH-21 protocols in adult patients with de novo nodal DLBCL with 2 or more signs of poor prognosis, as well as to determine the role of auto-HSCT in the consolidation of remission.Materials and methods. From 2015 to 2021, 164 patients were evaluated for randomization. The study included 140 patients from 13 Russian medical centers. 89 (76 %) patients with de novo nodal DLBCL: R-DAEPOCH-21 20 (22.5 %) patients; R-DAEPOCH-21 + auto-HSCT 21 (23.5 %) patients; R-mNHL-BFM-90 20 (22.5 %) patients; R-mNHL-BFM-90 performed + auto-HSCT 28 (31.5 %) patients. In the high-intermediate and high-risk group, there were 12 (29.3 %) and 29 (70.7 %) patients on the R-DA-EPOCH-21 + auto-HSCT protocol and 15 (31.2 %) and 32 (66.7 %) on the R-mNHL-BFM-90 protocol + auto-HSCT, respectively.Results. The R-mNHL-BFM-90 protocol proved to be more effective. Complete remission in the high-risk group was achieved in 30 (93.7 %) patients versus 18 (62.0 %), there was no progression versus 3 (10.3 %) patients treated according to R-DA-EPOCH-21 (p = 0.0167). The five-year overall and event-free survival in the high-risk group was 97 % vs. 75 % (p = 0.01) and 97 % vs. 72 % (p = 0.0026), respectively. In the intermediate risk group, the results of therapy did not differ. The toxicity of the R-mNHL-BFM-90 protocol exceeded the toxicity of R-DA-EPOCH-21 only in neutropenic fever (p = 0.04) and grade 3–4 thrombocytopenia (p = 0.0009).Conclusion. The R-mNHL-BFM-90 protocol is effective for the treatment of patients with nodal de novo DLBCL diffuse large B-cell lymphoma of high-risk adults; its toxicity is acceptable. However, on the R-DA-EPOCH-21 therapy, the results of therapy are unsatisfactory. The R-DA-EPOCH-21 protocol with auto-HSCT was more effective than without auto-HSCT, however, due to the small number of patients, the results were unpresentative. The results of therapy according R-mNHL-BFM-90 protocol with auto-HSCT and without auto-HSCT were not differ.
- 27 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 392-409
Open AccessMulticenter randomized controlled (comparative) open prospective study to evaluate the efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cell transplantation programs in untreated patients with de novo diffuse B-cell large cell lymphoma with signs of poor prognosis (final results)
Introduction. The R-NHL-BFM-90 protocol has been successfully used for the treatment of Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) in children and adolescents, as well as adult T-cell lymphomas. The protocol was modified for the treatment of adult patients with de novo nodal DLBCL.Aim: to evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DA-EPOCH-21 protocols in adult patients with de novo nodal DLBCL with 2 or more signs of poor prognosis, as well as to determine the role of auto-HSCT in the consolidation of remission.Materials and methods. From 2015 to 2021, 164 patients were evaluated for randomization. The study included 140 patients from 13 Russian medical centers. 89 (76 %) patients with de novo nodal DLBCL: R-DAEPOCH-21 20 (22.5 %) patients; R-DAEPOCH-21 + auto-HSCT 21 (23.5 %) patients; R-mNHL-BFM-90 20 (22.5 %) patients; R-mNHL-BFM-90 performed + auto-HSCT 28 (31.5 %) patients. In the high-intermediate and high-risk group, there were 12 (29.3 %) and 29 (70.7 %) patients on the R-DA-EPOCH-21 + auto-HSCT protocol and 15 (31.2 %) and 32 (66.7 %) on the R-mNHL-BFM-90 protocol + auto-HSCT, respectively.Results. The R-mNHL-BFM-90 protocol proved to be more effective. Complete remission in the high-risk group was achieved in 30 (93.7 %) patients versus 18 (62.0 %), there was no progression versus 3 (10.3 %) patients treated according to R-DA-EPOCH-21 (p = 0.0167). The five-year overall and event-free survival in the high-risk group was 97 % vs. 75 % (p = 0.01) and 97 % vs. 72 % (p = 0.0026), respectively. In the intermediate risk group, the results of therapy did not differ. The toxicity of the R-mNHL-BFM-90 protocol exceeded the toxicity of R-DA-EPOCH-21 only in neutropenic fever (p = 0.04) and grade 3–4 thrombocytopenia (p = 0.0009).Conclusion. The R-mNHL-BFM-90 protocol is effective for the treatment of patients with nodal de novo DLBCL diffuse large B-cell lymphoma of high-risk adults; its toxicity is acceptable. However, on the R-DA-EPOCH-21 therapy, the results of therapy are unsatisfactory. The R-DA-EPOCH-21 protocol with auto-HSCT was more effective than without auto-HSCT, however, due to the small number of patients, the results were unpresentative. The results of therapy according R-mNHL-BFM-90 protocol with auto-HSCT and without auto-HSCT were not differ.
- 22 November 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 111 (3) , 116624
The first case of Aspergillus fumigatus with high-level resistance to voriconazole due to the TR46/Y121F/T289A mutation in the Russian Federation
- 22 November 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 111 (3) , 116624
The first case of Aspergillus fumigatus with high-level resistance to voriconazole due to the TR46/Y121F/T289A mutation in the Russian Federation
- Open Access
- 30 May 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (2) , 87‑99
In vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and Pseudomonas aeruginosa isolated from blood culture from patients with hematological diseases: results of a multicenter study
Background. Activity against Gram negative bacteria, including Pseudomonas aeruginosa, is required for first line antibiotic therapy in patients with febrile neutropenia.Aim. To study in vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and P. aeruginosa strains in patients with bloodstream infection and hematologic diseases.Materials and methods. Susceptibility of cefepime / sulbactam and biapenem in comparison to anibiotics used for febrile neutropenia was studied among Escherichia coli (n = 100), Klebsiella pneumoniae (n = 100), Enterobacter cloacae complex (n = 30), and P. aeruginosa (n = 70) isolated from blood culture (2017–2021) from patients with hematological diseases and infection in 4 Russian hospitals. Activity was determined by broth microdilution method, interpretation was according to Clinical and Laboratory Standards Institute (CLSI, 2022) and European Committee on Antimicrobial Susceptibility Testing (EUCAST , 2022) criteria, for cefepime / sulbactam we used cefepime criteria. The values of the minimum inhibitory concentration (MIC), MIC50 and MIC90 were studied.Results. MIC90 of cefepime / sulbactam were lower in comparison with piperacillin / tazobactam for E. coli without extended spectrum beta-lactamase (ESBL) production (0.125 μg / mL vs 1 μg / mL), K. pneumoniae without ESBL-production (0.125 μg / mL vs 2 μg / mL), K. pneumoniae with ESBL-production (32 μg / mL vs 128 μg / mL) with comparable frequency of resistant strains. For P. aeruginosa, preference of cefepime / sulbactam over piperacillin / tazobactam were found both by lower MIC90 (8 μg / mL vs 32 μg / mL) and by lower frequency of resistant strains according to EUCAST criteria (4.3 % vs 25.7 %). The MIC90 values of cefepime / sulbactam compared to cefepime and ceftazidime were 4 times lower for K. pneumoniae with ESBL-production and for Enterobacter cloacea complex, 2–4 times lower for P. aeruginosa, 64 times lower for E. coli with ESBL production.Values of biapenem MIC90 for E. coli without and with ESBL-production (0.032 μg / mL) were in intermediate position between meropenem and imipenem; for K. pneumoniae without ESBL-production – identical to imipenem (0.064 μg / mL), for K. pneumoniae with ESBL – minimal (0.064 μg / mL) against imipenem and meropenem; for E. cloacae – comparable to meropenem (0.032 μg / mL). For P. aeruginosa without carbapenemase production, the MIC50 / MIC90 values of biapenem (0.125 / 16 μg / mL) were minimal compared to meropenem (0.25 / 64 μg / mL) and imipenem (0.5 / 64 μg / mL).Conclusion. The favorable in vitro activity of cefepime / sulbactam and biapenem are fully comply with the requirements for febrile neutropenia.
- 30 May 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (2) , 87‑99
Open AccessIn vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and Pseudomonas aeruginosa isolated from blood culture from patients with hematological diseases: results of a multicenter study
Background. Activity against Gram negative bacteria, including Pseudomonas aeruginosa, is required for first line antibiotic therapy in patients with febrile neutropenia.Aim. To study in vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and P. aeruginosa strains in patients with bloodstream infection and hematologic diseases.Materials and methods. Susceptibility of cefepime / sulbactam and biapenem in comparison to anibiotics used for febrile neutropenia was studied among Escherichia coli (n = 100), Klebsiella pneumoniae (n = 100), Enterobacter cloacae complex (n = 30), and P. aeruginosa (n = 70) isolated from blood culture (2017–2021) from patients with hematological diseases and infection in 4 Russian hospitals. Activity was determined by broth microdilution method, interpretation was according to Clinical and Laboratory Standards Institute (CLSI, 2022) and European Committee on Antimicrobial Susceptibility Testing (EUCAST , 2022) criteria, for cefepime / sulbactam we used cefepime criteria. The values of the minimum inhibitory concentration (MIC), MIC50 and MIC90 were studied.Results. MIC90 of cefepime / sulbactam were lower in comparison with piperacillin / tazobactam for E. coli without extended spectrum beta-lactamase (ESBL) production (0.125 μg / mL vs 1 μg / mL), K. pneumoniae without ESBL-production (0.125 μg / mL vs 2 μg / mL), K. pneumoniae with ESBL-production (32 μg / mL vs 128 μg / mL) with comparable frequency of resistant strains. For P. aeruginosa, preference of cefepime / sulbactam over piperacillin / tazobactam were found both by lower MIC90 (8 μg / mL vs 32 μg / mL) and by lower frequency of resistant strains according to EUCAST criteria (4.3 % vs 25.7 %). The MIC90 values of cefepime / sulbactam compared to cefepime and ceftazidime were 4 times lower for K. pneumoniae with ESBL-production and for Enterobacter cloacea complex, 2–4 times lower for P. aeruginosa, 64 times lower for E. coli with ESBL production.Values of biapenem MIC90 for E. coli without and with ESBL-production (0.032 μg / mL) were in intermediate position between meropenem and imipenem; for K. pneumoniae without ESBL-production – identical to imipenem (0.064 μg / mL), for K. pneumoniae with ESBL – minimal (0.064 μg / mL) against imipenem and meropenem; for E. cloacae – comparable to meropenem (0.032 μg / mL). For P. aeruginosa without carbapenemase production, the MIC50 / MIC90 values of biapenem (0.125 / 16 μg / mL) were minimal compared to meropenem (0.25 / 64 μg / mL) and imipenem (0.5 / 64 μg / mL).Conclusion. The favorable in vitro activity of cefepime / sulbactam and biapenem are fully comply with the requirements for febrile neutropenia.
- Open Access
- 15 March 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (1) , 88-100
Risk of bloodstream infections in allogeneic hematopoietic cell transplant recipients according to gut mucosal colonization and fluoroquinolone implementation during neutropenia
Background. Higher rate of gram-negative bloodstream infections (BSI) have been recently documented from transplantation centers providing fluoroquinolone (FQ) prophylaxis.Aim. To define the incidence of BSI during neutropenia according to gut mucosal colonization with resistant gramnegative bacteria and FQ administration.Materials and methods. Of 284 allogeneic hematopoietic cell transplant recipients included in the study, 154 (54.2 %) were identified as colonized with resistant gram-negative bacteria, and 130 (45.8 %) patients as non-colonized. Resistant gram-negative bacteria included Enterobacterales with extended spectrum beta-lactamase production, carbapenem-resistant Enterobacterales, Stenotrophomonas maltophilia, and carbapenem-resistant strains of Pseudomonas aeruginosa. Colonized patients did not receive FQ prophylaxis (n = 147) except 7 patients who received FQ as sequential therapy due to residual inflammatory lung lesions. Among non-colonized patients 98 received FQ prophylaxis, whereas 32 did not.Results. Probability of gram-negative BSI (71.4 %; p 0.0001), and extended spectrum beta-lactamase-producing Enterobacterales BSI (57.1 %; p 0.0001) was significantly higher in colonized patients receiving FQ. No significant difference was found in probability of gram-positive BSI (p = 0.452). In multivariate analysis colonized patients with (hazard ratio (HR) 35.32; 95 % confidence interval (CI) 9.15–136.44; p 0.0001) or without FQ (HR 3.44; 95 % CI 1.15–10.31; p = 0.007), omission of FQ in non-colonized patients (HR 4.03; 95 % CI 1.08–15.00; p = 0.038), and active disease before allogeneic hematopoietic cell transplantation (HR 2.17; 95 % CI 1.03–4.63; p = 0.042) were associated with higher risk of gram-negative BSI, whereas mismatched unrelated donor transplantations were associated with higher gram-positive BSI risk (HR 3.84; 95 % CI 1.63–9.08; p = 0,009).Conclusion. Colonization with multiresistant gram-negative bacteria is a predictor of gram-negative BSI, including multiresistant pathogens, especially when FQ are prescribed during neutropenia, while in non-colonized patients FQ prophylaxis is an effective approach significantly reducing gram-negative BSI.
- 15 March 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (1) , 88-100
Open AccessRisk of bloodstream infections in allogeneic hematopoietic cell transplant recipients according to gut mucosal colonization and fluoroquinolone implementation during neutropenia
Background. Higher rate of gram-negative bloodstream infections (BSI) have been recently documented from transplantation centers providing fluoroquinolone (FQ) prophylaxis.Aim. To define the incidence of BSI during neutropenia according to gut mucosal colonization with resistant gramnegative bacteria and FQ administration.Materials and methods. Of 284 allogeneic hematopoietic cell transplant recipients included in the study, 154 (54.2 %) were identified as colonized with resistant gram-negative bacteria, and 130 (45.8 %) patients as non-colonized. Resistant gram-negative bacteria included Enterobacterales with extended spectrum beta-lactamase production, carbapenem-resistant Enterobacterales, Stenotrophomonas maltophilia, and carbapenem-resistant strains of Pseudomonas aeruginosa. Colonized patients did not receive FQ prophylaxis (n = 147) except 7 patients who received FQ as sequential therapy due to residual inflammatory lung lesions. Among non-colonized patients 98 received FQ prophylaxis, whereas 32 did not.Results. Probability of gram-negative BSI (71.4 %; p 0.0001), and extended spectrum beta-lactamase-producing Enterobacterales BSI (57.1 %; p 0.0001) was significantly higher in colonized patients receiving FQ. No significant difference was found in probability of gram-positive BSI (p = 0.452). In multivariate analysis colonized patients with (hazard ratio (HR) 35.32; 95 % confidence interval (CI) 9.15–136.44; p 0.0001) or without FQ (HR 3.44; 95 % CI 1.15–10.31; p = 0.007), omission of FQ in non-colonized patients (HR 4.03; 95 % CI 1.08–15.00; p = 0.038), and active disease before allogeneic hematopoietic cell transplantation (HR 2.17; 95 % CI 1.03–4.63; p = 0.042) were associated with higher risk of gram-negative BSI, whereas mismatched unrelated donor transplantations were associated with higher gram-positive BSI risk (HR 3.84; 95 % CI 1.63–9.08; p = 0,009).Conclusion. Colonization with multiresistant gram-negative bacteria is a predictor of gram-negative BSI, including multiresistant pathogens, especially when FQ are prescribed during neutropenia, while in non-colonized patients FQ prophylaxis is an effective approach significantly reducing gram-negative BSI.
- Open Access
- 9 March 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (2) , 204-213
Post-engraftment Bloodstream Infections After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Association with Mortality
Akhmedov M, et al. Infect Chemother. 2023 Mar;55:e9. https://doi.org/10.3947/ic.2022.0146
- 9 March 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (2) , 204-213
Open AccessPost-engraftment Bloodstream Infections After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Association with Mortality
Akhmedov M, et al. Infect Chemother. 2023 Mar;55:e9. https://doi.org/10.3947/ic.2022.0146